5-Dodecyloxy-3-(4-trifluoromethoxy-phenyl)-3H-(1,3,4)-oxadiazol-2-one | 590364-53-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 5-Dodecyloxy-3-(4-trifluoromethoxy-phenyl)-3H-(1,3,4)-oxadiazol-2-one
• 英文别名: 5-dodecoxy-3-[4-(trifluoromethoxy)phenyl]-1,3,4-oxadiazol-2-one
• CAS: 590364-53-7
• 化学式: C₂₁H₂₉F₃N₂O₄
• 分子量: 430.467
• InChiKey: DAQCUXYFZBBWOG-UHFFFAOYSA-N

物化性质

• 沸点：
  437.6±55.0 °C(Predicted)
• 密度：
  1.19±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  8.7
• 重原子数：
  30
• 可旋转键数：
  14
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.62
• 拓扑面积：
  60.4
• 氢给体数：
  0
• 氢受体数：
  8

反应信息

• 作为产物：
  描述：

  光气 、 氯甲酸十二烷基酯 、 4-三氟甲氧基苯肼 在 吡啶 作用下， 以 二氯甲烷 、 水 、 甲苯 为溶剂， 生成 5-Dodecyloxy-3-(4-trifluoromethoxy-phenyl)-3H-(1,3,4)-oxadiazol-2-one
  参考文献：
  名称：

  Substituted 3-phenyl-5-alkoxy-3H- (1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof

  摘要：

  本文描述了一种代替的3-苯基-5-烷氧基-3H-(1,3,4)-噁二唑-2-酮化合物，化学式为1,1，其中R1、R2、R3、R4和R5的定义如本文所述，以及包含该化合物的药物组合物和用于抑制胰脂肪酶或预防或治疗肥胖症的化合物的用途。

  公开号：

  US20030181433A1

文献信息

• [EN] 5-O-SUBSTITUTED 3-N-PHENYL-1,3,4-OXADIAZOLONES FOR MEDICAL USE<br/>[FR] 3-N-PHÉNYL-1,3,4-OXADIAZOLONES 5-O-SUBSTITUÉES POUR UNE UTILISATION MÉDICALE
  申请人：BIAL PORTELA & COMPANHIA S A

  公开号：WO2009084970A1

  公开（公告）日：2009-07-09

  The present invention relates to compounds having a 5-O-substituted 3-N-phenyl-1,3,4-oxadiazolone structural unit which have unexpectedly high level of inhibition of FAAH (fatty acid amide hydrolase). (I)

  本发明涉及具有5-O取代的3-N-苯基-1,3,4-噁二唑酮结构单元的化合物，其对FAAH（脂肪酸酰胺水解酶）具有意外高水平的抑制作用。
• Novel medical uses of compounds showing CB1-antagonistic activity and combination treatment involving said compounds
  申请人：Antel Jochen

  公开号：US20050124660A1

  公开（公告）日：2005-06-09

  The present invention relates to a novel medical use of compounds with CB 1 -receptor activity selected from the group of 4,5-dihydro-1H-pyrazole derivatives, 1H-Imidazole derivatives, thiazole derivatives and/or 1H-1,2,4-triazole-3-carboxamide derivatives, as each defined in the specification, or of a prodrug thereof, a tautomer thereof or a salt thereof, in the manufacture of medicaments for the treatment and/or prophylaxis of CB 1 receptor related diseases in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile, as well as in adolescent, patients. Furthermore, the invention pertains to the use of said compounds with CB 1 -receptor activity in combination with lipase inhibitors. Said compounds are particularly suitable in combination with lipase inhibitors in the manufacture of medicaments for the treatment and/or prophylaxis of obesity in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. Preferred lipase inhibitors are orlistat, panclicins, ATL-962 and/or lipstatin.

  本发明涉及一种新型医用化合物，该化合物具有CB1受体活性，所述化合物选自4,5-二氢-1H-吡唑衍生物、1H-咪唑衍生物、噻唑衍生物和/或1H-1,2,4-三唑-3-羧酰胺衍生物，如规范中所定义，或其前药、互变异构体或盐，用于制造治疗和/或预防CB1受体相关疾病的药物，适用于青少年患者，以及用于治疗和/或预防青少年和/或成年患者的药物诱导肥胖症。此外，本发明涉及将具有CB1受体活性的化合物与脂肪酶抑制剂结合使用。这些化合物与脂肪酶抑制剂结合使用特别适用于制造用于治疗和/或预防青少年或儿童患者的肥胖症的药物，以及用于治疗和/或预防青少年和/或成年患者的药物诱导肥胖症。优选的脂肪酶抑制剂是奥利司他、泛克立汀、ATL-962和/或脂肪酸盐酶抑制剂。
• Substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-ones, pharmaceutical composition and method for treating obesity thereof
  申请人：Schoenafinger Karl

  公开号：US06900233B2

  公开（公告）日：2005-05-31

  A substituted 3-phenyl-5-alkoxy-3H-(1,3,4)-oxadiazol-2-one, compound of formula 1, wherein R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein, pharmaceutical composition comprising the compound and use of the compound for inhibiting pancreatic lipase, or the prophylaxis or treatment of obesity are described.

  本文描述了一种代替的3-苯基-5-烷氧基-3H-(1,3,4)-噁二唑-2-酮化合物，化学式为1，其中R1、R2、R3、R4和R5如本文所定义，以及包含该化合物的药物组合物和用于抑制胰脂酶、预防或治疗肥胖症的该化合物的用途。
• Novel medical combination treatment of obesity involving 4,5-dihydro-1H-pyrazole derivatives having CB1-antagonistic activity
  申请人：Antel Jochen

  公开号：US20050143441A1

  公开（公告）日：2005-06-30

  The present invention relates to a novel medical use of e.g. 4,5-dihydro-1H-pyrazole compounds which are potent antagonists of the cannabis CB 1 -receptor in combination with lipase inhibitors. Said compounds are particularly suitable in combination with lipase inhibitors in the manufacture of medicaments for the treatment and/or prophylaxis of obesity in adolescent or in juvenile patients and/or for the treatment and/or prophylaxis of drug induced obesity in juvenile as well as in adolescent patients. The compounds have the general formula (I) wherein the group Bb represents sulfonyl or carbonyl, and the substituents R, R 1 , R 2 and R 3 , and the group Aa are defined as shown in the description. Preferred lipase inhibitors are orlistat, panclicins, ATL-962 and/or lipstatin.

  本发明涉及 4,5-二氢-1H-吡唑等化合物的新型医疗用途，这些化合物是大麻 CB1-1 的强效拮抗剂。 1 -受体的强效拮抗剂。所述化合物特别适合与脂肪酶抑制剂结合，用于制造治疗和/或预防青少年肥胖症和/或治疗和/或预防药物引起的青少年肥胖症的药物。这些化合物具有通式 (I) 其中基团 Bb 代表磺酰基或羰基，取代基 R、R 1 , R 2 和 R 3 和基团 Aa 的定义如说明所示。优选的脂肪酶抑制剂有奥利司他、泛环素、ATL-962 和/或脂肪司他丁。
• SUBSTITUIERTE 3-PHENYL-5-ALKOXY-1,3,4-OXADIAZOL-2-ONE SOWIE IHRE HERSTELLUNG UND VERWENDUNG IN ARZNEISTOFFEN
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1480960A1

  公开（公告）日：2004-12-01